Mumbai-based ImmunoACT, an IIT Bombay spin-off, hit profitability in its first year by launching NexCAR19, India’s first indigenous CAR‑T therapy. With ₹48 crore revenue and 250+ patients treated affordably, the biotech startup proves deep-science ventures can scale and succeed early, blending clinical innovation, local R&D, and accessible cancer care.